NewsRelease

JournalArticle Cites Cleanascite™ for Purificationof MonoclonalAntibody used in Prostate Cancer Research

MONMOUTHJUNCTION, NJ,November14, 2023 -- Biotech Support Group reports on a journal researcharticle describing the simplicity and efficiency of their lipidclarification technology for purifying a monoclonal antibody fromascites fluid.

Thecitation is:

Testa,Anna, et al. "TARGETINGTHE αVβ3/NgR2 PATHWAY IN NEUROENDOCRINE PROSTATE CANCER." MatrixBiology (2023).

Highlyaggressive, metastatic, neuroendocrine prostate cancer, is associatedwith limited treatment options and hence poor prognosis. The authorshave previously demonstrated that the αVβ3 integrin isover-expressed in neuroendocrine prostate cancer. They now show thatLM609, a monoclonal antibody that specifically targets the humanαVβ3 integrin, hinders the growth of neuroendocrine prostatecancer patient-derived xenografts invivo. Thearticle states “LM609 purification was performed as previouslydescribed. Briefly, LM609 ascites was cleaned with Cleanascite …,and recirculated over a Protein A column.” The report offers abetter understanding of integrin-directed signaling and cell-cellcommunication during cancer progression. Furthermore, the resultspave the way for new diagnostic and therapeutic perspectives forpatients affected by neuroendocrine prostate cancer.

“Whilemany other uses of Cleanascite™are now common, here it is employed for one of its first intendedapplications, toefficiently clear lipids from ascites fluid, to assist in thepurification of monoclonal antibodies.” states Swapan Roy, Ph.D.,President and Founder of Biotech Support Group.

Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords

Monoclonalantibody, ascites, lipidclarification, Cleanascite™.

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for expanding proteomic analysis.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area. For this market, keyproducts include: AlbuVoid™ and AlbuSorb™ PLUS foralbumin & IgG depletion, Cleanascite™for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobinremoval, and NRicher™ for low abundance and family specificproteome enrichment. For more information, go tohttp://www.biotechsupportgroup.com

Forbusiness development contact: Matthew Kuruc
732-274-2866[email protected]